Hansa Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 10/18 04:11

Hansa Biopharma (STO:HNSA) Third Quarter 2024 Results

Key Financial Results

  • Revenue: kr48.7m (up 113% from 3Q 2023).
  • Net loss: kr103.8m (loss narrowed by 59% from 3Q 2023).
  • kr1.53 loss per share (improved from kr4.78 loss in 3Q 2023).
earnings-and-revenue-growth
OM:HNSA Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hansa Biopharma EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) exceeded analyst estimates by 37%.

Looking ahead, revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Hansa Biopharma (including 1 which is potentially serious).